Phoenix Molecular Designs is a Vancouver-based biotechnology company founded by the renowned Breast Cancer researcher, Dr. Sandra Dunn. Committed to revolutionizing cancer treatment, the company focuses on developing targeted small molecule drugs to effectively combat Triple Negative Breast Cancer, offering a safer and more efficient alternative to current chemotherapies.

At Phoenix Molecular Designs, our mission is to improve the quality of life for patients by designing precise cancer therapeutics. Our groundbreaking work centers around developing novel drugs that target RSK (Ribosomal S6 Kinase), a pivotal factor in cancerous tumor growth and metastasis. This signaling pathway controls the growth of various types of cancer, including breast and prostate cancer.

With a particular emphasis on Triple Negative Breast Cancer, where RSK was initially discovered, we aim to address the limited treatment options beyond chemotherapy. Our lead candidate, PMD-026, has successfully completed a first-in-human clinical trial in breast cancer patients. With an extensive portfolio of patented cancer compounds, we are pioneers in the field of RSK inhibition.

Additionally, we streamline our products to market through the use of companion diagnostics, identifying cancer patients who will optimally benefit from RSK targeted therapies. Choose Phoenix Molecular Designs for personalized and alternative cancer therapeutics, providing hope and improved outcomes for patients